Age-dependent changes in noradrenergic locus coeruleus system in wild-type and APP23 transgenic mice

Neuroscience Letters

Volumn 463, Issue 1, 2009, Pages 93-97

  Szot, Patricia ^a   Van Dam, Debby ^b   White, Sylvia S ^a   Franklin, Allyn ^a   Staufenbiel, Matthias ^c   De Deyn, Peter Paul ^b,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c NOVARTIS PHARMA AG   (Switzerland)

^d MIDDELHEIM HOSPITAL   (Belgium)

Author keywords

Aging; Alzheimer's disease; APP23 transgenic; Locus coeruleus; Norepinephrine; Tyrosine hydroxylase

Indexed keywords

AMYLOID PRECURSOR PROTEIN; AMYLOID PRECURSOR PROTEIN 23; MESSENGER RNA; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CONTROLLED STUDY; GENE EXPRESSION; LOCUS CERULEUS; MALE; MOUSE; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; TRANSGENIC MOUSE; WILD TYPE;

AGING; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; LOCUS COERULEUS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; NOREPINEPHRINE; RNA, MESSENGER; TYROSINE 3-MONOOXYGENASE;

EID: 68249147908     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.07.055     Document Type: Article

References (58)

1. Adolfsson R., Gottfries C.G., Roos B.E., and Winblad B. Changes in the brain catecholamines in patients with dementia of Alzheimer's type. Br. J. Psychiatry 135 (1979) 216-223
2. Bezin L., Marcel D., Desgeorges S., Pujol J.-F., and Weissmann D. Singular subsets of locus coeruleus neurons may recover tyrosine hydroxylase phenotype transiently expressed during development. Mol. Brain Res. 76 (2000) 275-281
3. Bezin L., Marcel D., Rousset C., Pujol J.F., and Weissmann D. Quantitative study of tyrosine hydroxylase protein levels within the somatic area of the rat locus coeruleus during postnatal development. J. Neurosci. 14 (1994) 7502-7510
4. Bondareff W., Mountjoy C.Q., and Roth M. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology 32 (1982) 164-168
5. Bondolfi L., Calhoun M., Ermini F., Kuhn H.G., Wiederhold K.H., Walker L., Staufenbiel M., and Jucker M. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J. Neurosci. 15 (2002) 515-522
6. Calhoun M.E., Wiederhold K.H., Abramowski D., Phinney A.L., Probst A., Sturchler-Pierrat C., Staufenbiel M., Sommer B., and Jucker M. Neuron loss in APP transgenic mice. Nature 395 (1998) 755-756
7. Chan-Palay V., and Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J. Comp. Neurol. 287 (1989) 373-392
8. Chartier-Harlin M.-C., Crawford F., Houlden H., Warren A., Hughes D., Fidani L., Goate A., Rossor M., Roques P., Hardy J., and Mullan M. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 353 (1991) 844-846
9. Cizza G., Pacak K., Kvetnansky R., Palkovits M., Goldstein D.S., Brady L.S., Fukuhara K., Bergamini E., Kopin I.J., Blackman M.R., Chrousos G.P., and Gold P.W. Decreased stress responsivity of central and peripheral catecholaminergic systems in aged 344/N Fischer rats. J. Clin. Invest. 95 (1995) 1217-1224
10. Cross A.J., Crow T.J., Perry E.K., Perry R.H., Blessed G., and Tomlinson B.E. Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease. Br. Med. J. Clin. Res. Ed. 282 (1981) 93-94
11. Elrod R., Peskind E.R., DiGiacomo L., Brodkin K.I., Veith R.C., and Raskind M.A. Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. Am. J. Psychiatry 154 (1997) 25-30
12. German D.C., and Eisch A.J. Mouse models of Alzheimer's disease: insight into treatment. Rev. Neurosci. 15 (2004) 353-369
13. German D.C., Manaye K.F., White III C.L., Woodward D.J., McIntire D.D., Smith W.K., Kalaria R.N., and Mann D.M. Disease-specific patterns of locus coeruleus cell loss. Ann. Neurol. 32 (1992) 667-676
14. German D.C., Nelson O., Liang F., Liang C.L., and Games D. The PDAPP mouse model of Alzheimer's disease: locus coeruleus neuronal shrinkage. J. Comp. Neurol. 492 (2005) 469-476
15. Gibbs M.E., and Summers R.J. Role of adrenoceptor subtypes in memory consolidation. Prog. Neurobiol. 67 (2002) 345-391
16. Gottfries C.G., Adolfsson R., Aquilonius S.M., Carlsson A., Eckernäs S.A., Nordberg A., Oreland L., Svennerholm L., Wiberg A., and Winblad B. Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol. Aging 4 (1983) 261-271
17. Grima B., Lamouroux A., Blanot F., Biguet N.F., and Mallet J. Complete coding sequence of rat tyrosine hydroxylase mRNA. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 617-621
18. Heneka M.T., Ramanathan M., Jacobs A.H., Dumitrescu-Ozimek L., Bilkei-Gorzo A., Debeir T., Sastre M., Galldiks N., Zimmer A., Hoehn M., Heiss W.D., Klockgether T., and Staufenbiel M. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J. Neurosci. 26 (2006) 1343-1354
19. Hoogendijk W.J., Feenstra M.G., Botterblom M.H., Gilhuis J., Sommer I.E., Kamphorst W., Eikelenboom P., and Swaab D.F. Increased activity of surviving locus ceruleus neurons in Alzheimer's disease. Ann. Neurol. 45 (1999) 82-91
20. Kelly P.H., Bondolfi L., Hunziker D., Schlecht H.P., Carver K., Maguire E., Abramowski D., Wiederhold K.H., Sturchler-Pierrat C., Jucker M., Bergmann R., Staufenbiel M., and Sommer B. Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiol. Aging 24 (2003) 365-378
21. Lalonde R., Dumont M., Staufenbiel M., Sturchler-Pierrat C., and Strazielle C. Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation. Brain Res. 956 (2002) 36-44
22. Liu Y., Yoo M.-J., Savonenko A., Stirling W., Price D.L., Borchelt D.R., Mamounas L., Lyons W.E., Blue M., and Lee M.K. Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 28 (2008) 13805-13814
23. Mann D.M., Lincoln J., Yates P.O., Stamp J.E., and Toper S. Changes in the monoamine containing neurones of the human CNS in senile dementia. Br. J. Psychiatry 136 (1980) 533-541
24. Mann J.J., Stanley M., Neophytides A., de Leon M.J., Ferris S.H., and Gershon S. Central amine metabolism in Alzheimer's disease: in vivo relationship to cognitive deficit. Neurobiol. Aging 2 (1981) 57-60
25. Marcyniuk B., Mann D.M., and Yates P.O. The topography of cell loss from locus caeruleus in Alzheimer's disease. J. Neurol. Sci. 76 (1986) 335-345
26. Mullan M., Houlden H., Windelspecht M., Fidani L., Lombardi C., Diaz P., Rossor M., Crook R., Hardy J., Duff K., and Crawford F. A locus for familial early-onset Alzheimer's disease on the long arm of chromosome 14, proximal to the α1-antichymotrypsin gene. Nat. Genet. 2 (1992) 340-342
27. O'Neil J.N., Mouton P.R., Tizabi Y., Ottinger M.A., Lei D.L., Ingram D.K., and Manaye K.F. Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice. J. Chem. Neuroanat. 34 (2007) 102-107
28. Palmer A.M., Francis P.T., Bowen D.M., Benton J.S., Neary D., Mann D.M., and Snowden J.S. Catecholaminergic neurones assessed ante-mortem in Alzheimer's disease. Brain Res. 414 (1987) 365-375
29. Perry E.K., Blessed G., Tomlinson B.E., Perry R.H., Crow T.J., Cross A.J., Dockray G.J., Dimaline R., and Arregui A. Neurochemical activities in human temporal lobe related to aging and Alzheimer's-type changes. Neurobiol. Aging 2 (1981) 251-256
30. Pinos H., Collado P., Rodriguez-Zafra M., Rodriguez C., Segovia S., and Guillamon A. The development of sex differences in the locus coeruleus of the rat. Brain Res. Bull. 56 (2001) 73-78
31. Prut L., Abramowski D., Krucker T., Levy C.L., Roberts A.J., Staufenbiel M., and Wiessner C. Aged APP23 mice show a delay in switching to the use of a strategy in the Barnes maze. Behav. Brain Res. 179 (2007) 107-110
32. Raskind M.A., Peskind E.R., Halter J.B., and Jimerson D.C. Norepinephrine and MHPG levels in CSF and plasma in Alzheimer's disease. Arch. Gen. Psychiatry 41 (1984) 343-346
33. Reinikainen K.J., Paljarvi L., Huuskonen M., Soininen H., Laakso M., and Reikkinen P. A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease. J. Neurol. Sci. 84 (1988) 101-116
34. Russo-Neustadt A., Zomorodian T.J., and Cotman C.W. Preserved cerebellar tyrosine hydroxylase-immunoreactive neuronal fibers in a behaviourally aggressive subgroup of Alzheimer's disease patients. Neuroscience 87 (1998) 55-61
35. Saito K., Shimada M., Kitahama K., and Maeda T. Postnatal development of adrenergic terminals in rat locus coeruleus, with special reference to growth of noradrenergic neurons. Brain Res. Dev. Brain Res. 96 (1996) 241-248
36. 693, and PRIG gene mutations are rare in Alzheimer's disease. Am. J. Genet. 49 (1991) 511-517
37. Shores M.M., White S.S., Veith R.C., and Szot P. Tyrosine hydroxylase mRNA is increased in old age and norepinephrine uptake transporter mRNA is decreased in middle age in locus coeruleus of Brown-Norway rats. Brain Res. 826 (1999) 143-147
38. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., and Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 13287-13292
39. Szapacs M.E., Numis A.L., and Andrews A.M. Late onset loss of hippocampal 5-HT and NE is accompanied by increases in BDNF protein expression in mice co-expressing mutant APP and PS1. Neurobiol. Dis. 16 (2004) 572-580
40. Szot P., White S.S., Greenup J.L., Leverenz J.B., Peskind E.R., and Raskind M.A. Compensatory changes in the noradrenergic nervous system in the locus coeruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J. Neurosci. 26 (2006) 467-478
41. Szot P., White S.S., Greenup J.L., Leverenz J.B., Peskind E.R., and Raskind M.A. Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes. Neuroscience 146 (2007) 471-480
42. Szot P., White S.S., and Veith R.C. Effect of pentylenetetrazol on the expression of tyrosine hydroxylase mRNA and norepinephrine and dopamine transporter mRNA. Brain Res. Mol. Brain Res. 44 (1997) 46-54
43. Tohgi H., Ueno M., Abe T., Takahashi S., and Nozaki Y. Concentrations of monoamines and their metabolites in the cerebrospinal fluid from patients with senile dementia of the Alzheimer type and vascular dementia of the Binswanger type. J. Neural. Transm. Parkinson Dis. Dement. Sect. 4 (1992) 69-77
44. Tomlinson B.E., Irving D., and Blessed G. Cell loss in the locus coeruleus in senile dementia of Alzheimer type. J. Neurol. Sci. 49 (1981) 419-428
45. Touret M., Valatx J.L., and Jouvet M. The locus coeruleus: a quantitative and genetic study in mice. Brain Res. 250 (1982) 353-357
46. Tümer N., Demirel H.A., Serova L., Sabban E.L., Broxson C.S., and Powers S.K. Gene expression of catecholamine biosynthetic enzymes following exercise: modulation by age. Neuroscience 103 (2001) 703-711
47. Unnerstall J.R., and Long M.M. Differential effects of the intraventricular administration of 6-hydroxydopamine on the induction of type II beta-tubulin and tyrosine hydroxylase mRNA in the locus coeruleus of the aging Fischer 344 rat. J. Comp. Neurol. 364 (1996) 363-381
48. Van Dam D., Abramowski D., Staufenbiel M., and De Deyn P.P. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology (Berl.) 180 (2005) 177-190
49. Van Dam D., D'Hooge R., Staufenbiel M., Van Ginneken C., Van Meir F., and De Deyn P.P. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur. J. Neurosci. 17 (2003) 388-396
50. Van Dam D., and De Deyn P.P. Drug discovery in dementia: the role of rodent models. Nat. Rev. Drug Discov. 5 (2006) 956-970
51. Van Dam D., Marescau B., Engelborghs S., Cremers T., Mulder J., Staufenbiel M., and De Deyn P.P. Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models. Neurochem. Int. 46 (2005) 409-422
52. Van Dam D., Vloeberghs E., Abramowski D., Staufenbiel M., and De Deyn P.P. APP23 mice as a model of Alzheimer's disease: an example of a transgenic approach to modeling a CNS disorder. CNS Spectr. 10 (2005) 207-222
53. Vloeberghs E., Coen K., Van Dam D., and De Deyn P.P. Validation of the APP23 transgenic mouse model of Alzheimer's disease through evaluation of risperidone treatment on aggressive behaviour. Arzneimittelforschung 58 (2008) 265-268
54. Vloeberghs E., Van Dam D., Coen K., Staufenbiel M., and De Deyn P.P. Aggressive male APP23 mice modeling behavioral alterations in dementia. Behav. Neurosci. 120 (2006) 1380-1383
55. Vloeberghs E., Van Dam D., D'Hooge R., Staufenbiel M., and De Deyn P.P. APP23 mice display working memory impairment in the plus-shaped water maze. Neurosci. Lett. 407 (2006) 6-10
56. Vloeberghs E., Van Dam D., Engelborghs S., Nagels G., Staufenbiel M., and De Deyn P.P. Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances. Eur. J. Neurosci. 20 (2004) 2757-2766
57. Vloeberghs E., Van Dam D., Franck F., Serroyen J., Geert M., Staufenbiel M., and De Deyn P.P. Altered ingestive behavior, weight changes, and intact olfactory sense in an APP overexpression model. Behav. Neurosci. 122 (2008) 491-497
58. Vloeberghs E., Van Dam D., Franck F., Staufenbiel M., and De Deyn P.P. Mood and male sexual behaviour in the APP23 model of Alzheimer's disease. Behav. Brain Res. 180 (2007) 146-151